SG11201805380YA - Urea-based prostate specific membrane antigen (psma) inhibitors for imaging and therapy - Google Patents
Urea-based prostate specific membrane antigen (psma) inhibitors for imaging and therapyInfo
- Publication number
- SG11201805380YA SG11201805380YA SG11201805380YA SG11201805380YA SG11201805380YA SG 11201805380Y A SG11201805380Y A SG 11201805380YA SG 11201805380Y A SG11201805380Y A SG 11201805380YA SG 11201805380Y A SG11201805380Y A SG 11201805380YA SG 11201805380Y A SG11201805380Y A SG 11201805380YA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- pennsylvania
- formula
- psma
- philadelphia
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Optics & Photonics (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Genetics & Genomics (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyridine Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
- Nuclear Medicine (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562273786P | 2015-12-31 | 2015-12-31 | |
| US15/385,490 US10688200B2 (en) | 2015-12-31 | 2016-12-20 | Urea-based prostate specific membrane antigen (PSMA) inhibitors for imaging and therapy |
| PCT/US2016/068327 WO2017116994A1 (en) | 2015-12-31 | 2016-12-22 | Urea-based prostate specific membrane antigen (psma) inhibitors for imaging and therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201805380YA true SG11201805380YA (en) | 2018-07-30 |
Family
ID=59225798
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201805380YA SG11201805380YA (en) | 2015-12-31 | 2016-12-22 | Urea-based prostate specific membrane antigen (psma) inhibitors for imaging and therapy |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US10688200B2 (ja) |
| EP (1) | EP3397968B1 (ja) |
| JP (1) | JP6850027B2 (ja) |
| KR (1) | KR20180098373A (ja) |
| CN (1) | CN108541302B (ja) |
| AU (2) | AU2016380151A1 (ja) |
| CA (1) | CA3010295C (ja) |
| DK (1) | DK3397968T3 (ja) |
| EA (1) | EA201891544A1 (ja) |
| HK (1) | HK1255215A1 (ja) |
| IL (1) | IL260342A (ja) |
| MX (1) | MX2018008168A (ja) |
| SG (1) | SG11201805380YA (ja) |
| WO (1) | WO2017116994A1 (ja) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT4095130T (lt) | 2013-10-18 | 2024-04-25 | Novartis Ag | Žymėti prostatos specifinio membranos antigeno (psma) inhibitoriai, jų naudojimas kaip vizualizavimo medžiagų ir farmacinių medžiagų prostatos vėžiui gydyti |
| US10688200B2 (en) | 2015-12-31 | 2020-06-23 | Five Eleven Pharma Inc. | Urea-based prostate specific membrane antigen (PSMA) inhibitors for imaging and therapy |
| KR20230147751A (ko) | 2016-03-22 | 2023-10-23 | 더 존스 홉킨스 유니버시티 | 전립선 암의 내부방사선요법을 위한 전립선-특이적 막 항원 표적화된 고-친화성 제제 |
| EP3618867A4 (en) | 2017-05-02 | 2021-01-20 | Cornell University | METHODS AND REAGENTS FOR AGAINST TUMOR WITH HIGHER EFFICIENCY AND LOWER TOXICITY |
| JP2020522506A (ja) * | 2017-05-30 | 2020-07-30 | ザ・ジョンズ・ホプキンス・ユニバーシティ | 前立腺がんの内部放射線療法のための前立腺特異的膜抗原をターゲットとした高親和性薬剤 |
| JOP20200135A1 (ar) | 2017-12-11 | 2020-06-02 | Univ Muenchen Tech | مركبات psma الترابطية للتصوير والعلاج الإشعاعي الداخلي |
| US20190184040A1 (en) * | 2017-12-15 | 2019-06-20 | Wisconsin Alumni Research Foundation | Targeted Macrocyclic Agents for Dual Modality PET and MRI Imaging of Cancer |
| MX2018003175A (es) * | 2018-03-14 | 2019-09-16 | Instituto Nac De Investigaciones Nucleares | 177lu-dota-hynic-ipsma como un radiofarmaco terapeutico dirigido al antigeno prostatico especifico de membrana. |
| CN109438517B (zh) * | 2018-12-27 | 2021-01-08 | 北京久杰净化工程技术有限公司 | 一种与羰基金属核心配位的双功能连接剂的配合物及其制备方法 |
| WO2020220023A1 (en) * | 2019-04-26 | 2020-10-29 | Five Eleven Pharma Inc. | Prostate-specific membrane antigen (psma) inhibitors as diagnostic and radionuclide therapeutic agents |
| AU2020296488A1 (en) | 2019-06-21 | 2022-01-20 | Provincial Health Services Authority | Radiolabeled compounds targeting the prostate-specific membrane antigen |
| JP2023514333A (ja) * | 2020-02-18 | 2023-04-05 | エンドサイト・インコーポレイテッド | Ｐｓｍａ発現がんを処置する方法 |
| WO2022072292A1 (en) * | 2020-10-01 | 2022-04-07 | Cornell University | Methods and compositions for increasing uptake, internalization, and/or retention of small molecule ligands |
| CN112358422B (zh) * | 2020-10-16 | 2023-06-23 | 中国辐射防护研究院 | 一种新型螯合剂nbed的制备方法 |
| CN117561448A (zh) * | 2021-03-17 | 2024-02-13 | 五一一制药股份有限公司 | 一种[18F]AlF标记的PSMA靶向分子探针及其制备方法 |
| CN113372285A (zh) * | 2021-05-28 | 2021-09-10 | 西南医科大学附属医院 | 前列腺特异性膜抗原抑制剂、其放射性核素标记物及制法和应用 |
| CN114436905A (zh) * | 2022-01-24 | 2022-05-06 | 攀枝花学院 | 3-醛基-4-羟基苯乙酸甲酯的纯化方法 |
| CN116514735A (zh) * | 2022-01-30 | 2023-08-01 | 晶核生物医药科技(南京)有限公司 | 一种肽脲素衍生物、含其的药物组合物及其应用 |
| CN114874122A (zh) * | 2022-05-31 | 2022-08-09 | 南京航空航天大学 | 一种新的小分子抑制剂及其制备方法和应用 |
| WO2024021556A1 (zh) * | 2023-02-02 | 2024-02-01 | 北京师范大学 | 一种靶向前列腺特异性膜抗原的放射性金属配合物及其标记配体 |
| CN116507630A (zh) * | 2023-02-14 | 2023-07-28 | 北京师范大学 | 含硝基芳香杂环基团的psma靶向放射性金属配合物及其制备 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1472541E (pt) | 2002-01-10 | 2009-12-21 | Univ Johns Hopkins | Agentes de imagiologia e métodos de imagiologia de naaladase de psma |
| WO2010022249A2 (en) | 2008-08-20 | 2010-02-25 | Ensemble Discovery Corporation | Macrocyclic compounds for inhibition of tumor necrosis factor alpha |
| CN107325127B (zh) * | 2011-06-15 | 2020-09-01 | 癌靶技术有限责任公司 | 螯合的psma抑制剂 |
| CA2844151C (en) | 2011-08-05 | 2022-11-29 | John W. Babich | Radiolabeled prostate specific membrane antigen inhibitors |
| CN113149921A (zh) * | 2011-11-30 | 2021-07-23 | 约翰霍普金斯大学 | 前列腺特异性膜抗原(psma)的同源多价抑制剂和异源多价抑制剂以及其用途 |
| CN108042811A (zh) * | 2012-11-15 | 2018-05-18 | 恩多塞特公司 | 用于治疗由psma表达细胞引起的疾病的共轭物 |
| HUE035739T2 (en) * | 2013-01-14 | 2018-05-28 | Molecular Insight Pharm Inc | Triazine-based radiopharmaceuticals and radiological imaging agents |
| US10406246B2 (en) | 2013-10-17 | 2019-09-10 | Deutsches Kresbsforschungszentrum | Double-labeled probe for molecular imaging and use thereof |
| LT4095130T (lt) | 2013-10-18 | 2024-04-25 | Novartis Ag | Žymėti prostatos specifinio membranos antigeno (psma) inhibitoriai, jų naudojimas kaip vizualizavimo medžiagų ir farmacinių medžiagų prostatos vėžiui gydyti |
| EP2862857A1 (en) * | 2013-10-18 | 2015-04-22 | Deutsches Krebsforschungszentrum | Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
| SG10201803618RA (en) * | 2013-11-14 | 2018-06-28 | Endocyte Inc | Compounds for positron emission tomography |
| US10683272B2 (en) * | 2014-05-06 | 2020-06-16 | The Johns Hopkins University | Metal/radiometal-labeled PSMA inhibitors for PSMA-targeted imaging and radiotherapy |
| US10688200B2 (en) | 2015-12-31 | 2020-06-23 | Five Eleven Pharma Inc. | Urea-based prostate specific membrane antigen (PSMA) inhibitors for imaging and therapy |
-
2016
- 2016-12-20 US US15/385,490 patent/US10688200B2/en active Active
- 2016-12-22 MX MX2018008168A patent/MX2018008168A/es unknown
- 2016-12-22 AU AU2016380151A patent/AU2016380151A1/en not_active Abandoned
- 2016-12-22 EP EP16882430.8A patent/EP3397968B1/en active Active
- 2016-12-22 KR KR1020187021593A patent/KR20180098373A/ko not_active Application Discontinuation
- 2016-12-22 DK DK16882430.8T patent/DK3397968T3/da active
- 2016-12-22 JP JP2018534552A patent/JP6850027B2/ja active Active
- 2016-12-22 SG SG11201805380YA patent/SG11201805380YA/en unknown
- 2016-12-22 EA EA201891544A patent/EA201891544A1/ru unknown
- 2016-12-22 CN CN201680079844.7A patent/CN108541302B/zh active Active
- 2016-12-22 CA CA3010295A patent/CA3010295C/en active Active
- 2016-12-22 WO PCT/US2016/068327 patent/WO2017116994A1/en active Application Filing
-
2018
- 2018-06-28 IL IL260342A patent/IL260342A/en unknown
- 2018-11-09 HK HK18114343.5A patent/HK1255215A1/zh unknown
-
2023
- 2023-06-13 AU AU2023203682A patent/AU2023203682A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3010295C (en) | 2023-09-26 |
| WO2017116994A1 (en) | 2017-07-06 |
| US20170189568A1 (en) | 2017-07-06 |
| CA3010295A1 (en) | 2017-07-06 |
| JP2019508374A (ja) | 2019-03-28 |
| HK1255215A1 (zh) | 2019-08-09 |
| MX2018008168A (es) | 2019-02-20 |
| CN108541302A (zh) | 2018-09-14 |
| EA201891544A1 (ru) | 2018-11-30 |
| EP3397968A1 (en) | 2018-11-07 |
| CN108541302B (zh) | 2023-02-14 |
| IL260342A (en) | 2018-08-30 |
| US10688200B2 (en) | 2020-06-23 |
| AU2016380151A1 (en) | 2018-07-19 |
| EP3397968A4 (en) | 2019-11-27 |
| KR20180098373A (ko) | 2018-09-03 |
| AU2023203682A1 (en) | 2023-07-06 |
| EP3397968B1 (en) | 2021-09-29 |
| DK3397968T3 (da) | 2021-11-01 |
| JP6850027B2 (ja) | 2021-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201805380YA (en) | Urea-based prostate specific membrane antigen (psma) inhibitors for imaging and therapy | |
| SG11201907544VA (en) | Jak inhibitors containing a 4-membered heterocyclic amide | |
| SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201908719QA (en) | Biomarkers and car t cell therapies with enhanced efficacy | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201810983PA (en) | Novel heterocyclic derivatives useful as shp2 inhibitors | |
| SG11201808582RA (en) | Pyrrolotriazine compounds as tam inhibitors | |
| SG11201804758QA (en) | Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab | |
| SG11201804170RA (en) | Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders | |
| SG11201804934PA (en) | Novel Compounds | |
| SG11201804152RA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201805645QA (en) | Lsd1 inhibitors | |
| SG11201807301SA (en) | Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitors | |
| SG11201803920TA (en) | Compounds and compositions useful for treating disorders related to ntrk | |
| SG11201810420YA (en) | Antibodies to alpha-synuclein and uses thereof | |
| SG11201408821SA (en) | Selective pi3k delta inhibitors | |
| SG11201407900WA (en) | Benzo [c] isoxazoloazepine bromodomain inhibitors and uses thereof | |
| SG11201806583XA (en) | Compositions containing tucaresol or its analogs | |
| SG11201408261UA (en) | Syringe | |
| SG11201809751XA (en) | Egfr inhibitor compounds | |
| SG11201803627XA (en) | N-substituted indole derivatives as pge2 receptor modulators | |
| SG11201908602UA (en) | Combination therapy for the treatment of solid and hematological cancers | |
| SG11201402986RA (en) | Kinase inhibitors | |
| SG11201907356SA (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
| SG11201408750VA (en) | NOVEL FUSED PYRIDINE DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS |